Global Isosorbide Mononitrate Market Professional Survey Report 2019

2 Global Isosorbide Mononitrate Quarterly Market Size Analysis

• 2.1 Isosorbide Mononitrate Business Impact Assessment - COVID-19
  • 2.1.1 Global Isosorbide Mononitrate Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Isosorbide Mononitrate Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Isosorbide Mononitrate Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Isosorbide Mononitrate Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Isosorbide Mononitrate Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Isosorbide Mononitrate Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Isosorbide Mononitrate Market
• 3.5 Key Manufacturers Isosorbide Mononitrate Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Isosorbide Mononitrate Segments, By Type

• 4.1 Introduction
  • 1.4.1 10 mg Tablet
  • 1.4.2 20 mg Tablet
• 4.2 By Type, Global Isosorbide Mononitrate Market Size, 2019-2021
  • 4.2.1 By Type, Global Isosorbide Mononitrate Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Isosorbide Mononitrate Price, 2020-2021

5 Impact of Covid-19 on Isosorbide Mononitrate Segments, By Application

• 5.1 Overview
  • 5.5.1 Treatment of angina pectoris
  • 5.5.2 Others
• 5.2 By Application, Global Isosorbide Mononitrate Market Size, 2019-2021
  • 5.2.1 By Application, Global Isosorbide Mononitrate Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Isosorbide Mononitrate Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Teva
  • 7.1.1 Teva Business Overview
  • 7.1.2 Teva Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.1.3 Teva Isosorbide Mononitrate Product Introduction
  • 7.1.4 Teva Response to COVID-19 and Related Developments
• 7.2 Merck
  • 7.2.1 Merck Business Overview
  • 7.2.2 Merck Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.2.3 Merck Isosorbide Mononitrate Product Introduction
  • 7.2.4 Merck Response to COVID-19 and Related Developments
• 7.3 Nesher Pharmaceuticals
  • 7.3.1 Nesher Pharmaceuticals Business Overview
  • 7.3.2 Nesher Pharmaceuticals Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.3.3 Nesher Pharmaceuticals Isosorbide Mononitrate Product Introduction
  • 7.3.4 Nesher Pharmaceuticals Response to COVID-19 and Related Developments
• 7.4 Taj pharmaceutical
  • 7.4.1 Taj pharmaceutical Business Overview
  • 7.4.2 Taj pharmaceutical Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.4.3 Taj pharmaceutical Isosorbide Mononitrate Product Introduction
  • 7.4.4 Taj pharmaceutical Response to COVID-19 and Related Developments
• 7.5 AMRI
  • 7.5.1 AMRI Business Overview
  • 7.5.2 AMRI Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.5.3 AMRI Isosorbide Mononitrate Product Introduction
  • 7.5.4 AMRI Response to COVID-19 and Related Developments
• 7.6 Intas Pharmaceuticals
  • 7.6.1 Intas Pharmaceuticals Business Overview
  • 7.6.2 Intas Pharmaceuticals Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.6.3 Intas Pharmaceuticals Isosorbide Mononitrate Product Introduction
  • 7.6.4 Intas Pharmaceuticals Response to COVID-19 and Related Developments
• 7.7 Sandoz
  • 7.7.1 Sandoz Business Overview
  • 7.7.2 Sandoz Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.7.3 Sandoz Isosorbide Mononitrate Product Introduction
  • 7.7.4 Sandoz Response to COVID-19 and Related Developments
• 7.8 Globus Remedies
  • 7.8.1 Globus Remedies Business Overview
  • 7.8.2 Globus Remedies Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.8.3 Globus Remedies Isosorbide Mononitrate Product Introduction
  • 7.8.4 Globus Remedies Response to COVID-19 and Related Developments
• 7.9 Intas Pharmaceuticals
  • 7.9.1 Intas Pharmaceuticals Business Overview
  • 7.9.2 Intas Pharmaceuticals Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.9.3 Intas Pharmaceuticals Isosorbide Mononitrate Product Introduction
  • 7.9.4 Intas Pharmaceuticals Response to COVID-19 and Related Developments
• 7.10 Shandong Fangming Pharmaceutical Group
  • 7.10.1 Shandong Fangming Pharmaceutical Group Business Overview
  • 7.10.2 Shandong Fangming Pharmaceutical Group Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.10.3 Shandong Fangming Pharmaceutical Group Isosorbide Mononitrate Product Introduction
  • 7.10.4 Shandong Fangming Pharmaceutical Group Response to COVID-19 and Related Developments
• 7.11 ReYoung Pharmaceutical
  • 7.11.1 ReYoung Pharmaceutical Business Overview
  • 7.11.2 ReYoung Pharmaceutical Isosorbide Mononitrate Quarterly Production and Revenue, 2020
  • 7.11.3 ReYoung Pharmaceutical Isosorbide Mononitrate Product Introduction
  • 7.11.4 ReYoung Pharmaceutical Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Isosorbide Mononitrate Supply Chain Analysis
  • 8.1.1 Isosorbide Mononitrate Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Isosorbide Mononitrate Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Isosorbide Mononitrate Distribution Channels
  • 8.2.2 Covid-19 Impact on Isosorbide Mononitrate Distribution Channels
  • 8.2.3 Isosorbide Mononitrate Distributors
• 8.3 Isosorbide Mononitrate Customers

9 Key Findings

10 Appendix

• 10.1 About Us